The Shudo Lab

Stanford Translational Heart Failure Research Laboratory

Stanford Cardiothoracic Surgery

Stanford School of Medicine Logo 2.png


Despite a growing armamentarium, there is still a lack of treatment options available for end-stage heart failure (ESHF) patients. With cardiac transplantation considered the only real cure for end-stage heart disease, the need for more viable and accessible therapies is increasing.

The Shudo laboratory strives to develop novel tissue engineering strategies, such as bioengineering, biomechanical, and biostatistical approaches to treat ESHF. We hope this research can be successfully translated to the clinical arena to impact progression to heart failure following myocardial infarction positively.

Moreover, our clinical focus is on the surgical treatment for ESHF, with a particular emphasis on the outcome of the orthotopic heart transplant, heart-lung transplant, and mechanical circulatory support (MCS), including extracorporeal membrane oxygenation (ECMO) and ventricular assist device (VAD).

In our unique interdisciplinary and collaborative research, from bench molecular and cellular biology through tissue engineering to bedside surgery, we envision a better quality of life for heart failure patients.



Tissue Engineering for Heart Failure Research

Bio-mechanical approach using 3D
Bio-fabrication system to create scaffold-free designed structure

With the invention of the 3D printer, scaffold-based solutions have significantly improved tissue engineering and regenerative medicine. However, these biomaterial-based interventions often entail problems, including imitations in materials used to create scaffolds, immunogenicity triggered by synthetic materials, and scaffold degradation in vivo. Thus, their relatively short lifespan and narrow therapeutic application limit their success as efficient treatments in a clinical setting. 

To overcome such problems, we are combining stem cell biology with the 3D bio-fabrication system to create scaffold-free tissues. These living tissues have low toxicity and high capability to maintain physical and biomechanical properties required for tissue growth long term, augmenting their translatability.


Bio-statistical approach to seek for
the targeted signaling pathway
in reversed ventricular remodeling

A better understanding of the molecular and genetic basis of myocardial dysfunction has made gene-based therapy a promising treatment alternative for heart failure.  
Our laboratory utilizes the latest technologies in next-generation sequencing to analyze the gene expression in the cardiac tissue of the failing heart. We seek to uncover which genes are subject to changes in expression in response to an improvement in blood flow caused by the placement of a ventricular assist device (LVAD). Our virtuous cycle of the bench to bedside to bench again, combining genome sequencing with clinical data and biostatistics, will accelerate insights into the function of genetic variants and signaling pathways that could give rise to therapeutics to improve cardiac function without the need for invasive surgical procedures. 


Bio-engineering approach to induce robust angiogenesis using bi-layered stem cell and cell sheet technology 

Despite many currently available therapeutics to treat heart failure, such as biomimetic scaffolds made of natural or synthetic polymers, their limited mechanical and biodegradable properties, as well as high potential for immunological rejection, are still in question. Direct injection of stem cells or catheter-based intracoronary procedures also reported only modest therapeutic benefits due to poor localized cell survival after injection or lack of supported elements for mature vasculature.   

To improve bio-compatibility and bio-functionality, enhance angiogenesis and facilitate blood vessel maturation, we have been generating stem cell-derived bi-layer cell sheets to treat heart failure progression following myocardial infarction. We hope that the implantation of our unique, spatially oriented bi-layer cell sheet would support the retention of the implanted cells and help form mature vasculature, enhancing the therapeutic effects of the cell sheet technique on ischemic cardiomyopathy (ICM). 

Innovative computational approach
using Artificial Intelligence

A left ventricular assist device (LVAD) has emerged as a bridge to transplantation and a viable destination therapy for patients who have reached end-stage heart failure. Despite their contribution to improving the quality of patients' lives and prognosis, LVAD implantation still comes with a vast spectrum of long-term complications, particularly mortality after infection. The confined driveline infection (DLI) affecting the tissues around the driveline outlet can spread to other sites, worsening the disease's severity and becoming systemic.  

By using information technology, our laboratory incorporates artificial intelligence (AI) into patient management. The underlying technology is the installation of AI in our APP for detecting DLI. We hope to provide patients with an LVAD with a more efficient way to monitor their driveline conditions while decreasing their burden of frequent trips to a limited number of specialized hospitals. This early intervention will ultimately reduce the incidence of severe DLI conditions and improve patients' lives even further.  



Our multidisciplinary approach is driven by a team of creative and passionate individuals from diverse backgrounds.

Dr. Yasuhiro Shudo, M.D., Ph.D

Principal Investigator,
Cardiothoracic Surgeon

Sook's Headshot (Website)_edited_edited.

Hye Sook Shin, B.S.

Life Science Research Professional/
Lab Manager

Akshara Thakore, M.S.

Life Science Research Professional



Shudo Team
Shudo Team
press to zoom
2019 Shudo Lab Farewell Lunch
2019 Shudo Lab Farewell Lunch
press to zoom
Cell Sheet Implanted on LAD Infarct
Cell Sheet Implanted on LAD Infarct
press to zoom
Shudo Team
Shudo Team
press to zoom
Shudo Lab Halloween Pumpkin Contest - Winner
Shudo Lab Halloween Pumpkin Contest - Winner

2019 The Shudo lab won the first place in the CT Surgery Department 3rd Annual Pumpkin Carving Contest!

press to zoom
Transverse Section of Hearts
Transverse Section of Hearts

Sham vs. MI vs. MI+Cell Sheet Treatment (from left to right)

press to zoom
Stanford School of Medicine Logo 2.png


The Shudo lab is currently looking for postdoctoral researchers only. We will update you with more opportunities soon.​

February 7, 2021

Open Position for Postdoctoral Fellows

The Shudo Lab is seeking a postdoctoral researcher to accelerate tissue engineering studies. A competitive applicant for this position will be interested in one of the following fields: stem cell biology, biochemistry, bioengineering, biomechanical engineering, cardiac surgery, computational biology, bioinformatics, or biostatistics. Candidates must hold a Ph.D./M.D. from an accredited institution in a relevant research field, have strong laboratory, analytical, organizational, and communication skills, and be able to work independently, as well as part of a team. 

Please submit your CV with a brief description of your research interests and career goals to Dr. Yasuhiro Shudo (​


Yasuhiro Shudo, M.D., Ph.D

Cardiothoracic surgeon, Clinical assistant professor

Department of Cardiothoracic Surgery at Stanford University

Stanford University School of Medicine

300 Pasteur Drive
2nd Floor, Room A21
Stanford , CA 94305
Phone: (650) 723-5468

Hye Sook Shin

Lab Manager

Lab Location:

Falk Cardiovascular Research Center
870 Quarry Road Extension
Stanford CA, 94305

Falk Cardiovacular Research Center.png